| Page 31 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Background
Haematopoietic stem-cell transplantation (HSCT) recipients are considered at high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status, but data from large studies in HSCT recipients are lacking. This study describes the characteristics and outcomes of HSCT recipients after developing COVID-19.

Is blood transfusion safe during the COVID-19 pandemic?

Author(s): 
Josiane Bassil, Elie Rassy, Joseph Kattan
Primary Author: 
Bassil J
Journal Title: 
Future Science OA
Original Publication Date: 
Sep 2020

The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic has challenged healthcare systems to re-organize the management of patients in a short period. The causative pathogen of this pandemic is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of seven coronaviruses that can be found in humans. It is a rapidly mutating, enveloped, ssRNA, beta-coronavirus. The initial reports published after the pandemic spread showed a transmissibility rate of 2.2 and possibly low values of dispersion.

Bone Marrow Disease(s): 

Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series

Author(s): 
Martynova A, Chiu V, Mert M, Hermel D, Weitz IC
Primary Author: 
Martynova A
Journal Title: 
Annals of Hematology
Original Publication Date: 
Jan 2021

First-line treatment of

Bone Marrow Disease(s): 

One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

Author(s): 
Kulasekararaj AG, Hill A, Langemeijer S, Wells R, González Fernández FA, Gaya A, Ojeda Gutierrez E, Piatek CI, Mitchell L, Usuki K, Bosi A, Brodsky RA, Ogawa M, Yu J, Ortiz S, Röth A, Lee JW, Peffault de Latour R.
Primary Author: 
Kulasekararaj AG
Journal Title: 
European Journal of Haematology
Original Publication Date: 
Dec 2020

Ravulizumab every 8 weeks showed non-inferiority to eculizumab every 2 weeks in a 26-week, phase 3, randomized controlled trial in adults with

Bone Marrow Disease(s): 

Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria

Author(s): 
Gurnari C, Graham AC, Efanov A, Pagliuca S, Durrani J, Awada H, Patel BJ, Lichtin AE, Visconte V, Sekeres MA, Maciejewski JP
Primary Author: 
Gurnarci C
Journal Title: 
Blood, cells, molecules & diseases
Original Publication Date: 
Dec 2020

While red blood cells (RBCs) and granulocytes have been more studied, platelets and reticulocytes are not commonly used in

Bone Marrow Disease(s):